Raymond James lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $60 from $61 and keeps a Strong Buy rating on the shares. Ionis beat nicely in Q4, and the 2025 floor guidance for revenue and operating loss appears reasonable as Ionis transitions to more of a commercial story, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target lowered to $63 from $65 at BofA
- Ionis Pharmaceuticals price target lowered to $45 from $60 at BMO Capital
- Ionis Pharmaceuticals: Hold Rating Amid Revenue Growth, Competitive Pressures, and Delayed Catalysts
- Ionis Pharmaceuticals: Balancing Strong R&D Revenues with Market Challenges – Hold Rating Justified
- Ionis Pharmaceuticals price target lowered to $64 from $67 at Citi